Your browser is no longer supported. Please, upgrade your browser.
Settings
EGLT Egalet Corporation daily Stock Chart
EGLT [NASD]
Egalet Corporation
Index- P/E- EPS (ttm)-2.49 Insider Own1.60% Shs Outstand51.17M Perf Week-4.88%
Market Cap25.02M Forward P/E- EPS next Y-0.74 Insider Trans-0.11% Shs Float51.17M Perf Month-24.92%
Income-69.40M PEG- EPS next Q-0.28 Inst Own50.30% Short Float8.32% Perf Quarter-37.16%
Sales26.10M P/S0.96 EPS this Y44.40% Inst Trans-4.96% Short Ratio4.89 Perf Half Y-51.59%
Book/sh-0.70 P/B- EPS next Y36.10% ROA-46.90% Target Price3.00 Perf Year-81.41%
Cash/sh1.46 P/C0.34 EPS next 5Y- ROE152.20% 52W Range0.48 - 3.47 Perf YTD-51.11%
Dividend- P/FCF- EPS past 5Y-39.50% ROI-90.70% 52W High-85.91% Beta0.53
Dividend %- Quick Ratio2.20 Sales past 5Y85.20% Gross Margin80.30% 52W Low2.88% ATR0.05
Employees131 Current Ratio2.30 Sales Q/Q16.70% Oper. Margin- RSI (14)30.71 Volatility5.83% 8.39%
OptionableYes Debt/Eq- EPS Q/Q74.50% Profit Margin- Rel Volume0.55 Prev Close0.50
ShortableYes LT Debt/Eq- EarningsMay 08 BMO Payout- Avg Volume870.02K Price0.49
Recom2.50 SMA20-20.57% SMA50-25.25% SMA200-48.86% Volume481,676 Change-1.75%
Jan-03-18Downgrade Stifel Buy → Hold $6 → $1.50
Nov-09-17Downgrade Gabelli & Co Buy → Hold
Aug-10-17Reiterated Stifel Buy $14 → $6
May-12-17Upgrade Gabelli & Co Hold → Buy $9.50
Sep-13-16Initiated Gabelli & Co Buy $9.50
Nov-04-15Initiated Cantor Fitzgerald Buy
May-11-15Initiated Guggenheim Buy $24
Sep-24-14Reiterated Stifel Buy $20 → $18
Mar-03-14Initiated Stifel Buy $20
May-22-18 07:30AM  Report: Developing Opportunities within Integer, Sykes Enterprises, Protagonist Therapeutics, Egalet, Watsco, and Extra Space Storage Future Expectations, Projections Moving into 2018 GlobeNewswire
May-16-18 07:07PM  Breakeven On The Horizon For Egalet Corporation (NASDAQ:EGLT) Simply Wall St. -11.68%
May-14-18 11:00AM  EGLT: Partnerships and Formulary Adds Impressive; Waiting for Revenue Catch Up Zacks Small Cap Research
May-11-18 09:56PM  Edited Transcript of EGLT earnings conference call or presentation 8-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-08-18 06:07AM  Egalet: 1Q Earnings Snapshot Associated Press
06:02AM  Egalet Reports First Quarter 2018 Financial Results PR Newswire
May-07-18 06:02AM  Egalet Announces National Pharmacy Benefit Manager to Cover SPRIX® Nasal Spray and ARYMO® ER PR Newswire
May-02-18 06:02AM  Egalet to Present at the 3rd Annual Disruptive Growth & Healthcare Conference ACCESSWIRE
Apr-30-18 06:02AM  Egalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid Abuse PR Newswire
Apr-24-18 06:02AM  Egalet to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on May 8, 2018 PR Newswire
Apr-20-18 07:00AM  Free Post Earnings Research Report: Egalet's Q4 Top-Line Growth Beat Estimates ACCESSWIRE
Apr-17-18 04:02PM  Egalet Announces Two Large Northeast Regional Health Plans Placed ARYMO® ER in Preferred Formulary Position PR Newswire
Apr-02-18 10:30AM  EGLT: Costs Down, Revenues Up, Partnerships Expanding Zacks Small Cap Research
Mar-28-18 07:40AM  Factors of Influence in 2018, Key Indicators and Opportunity within Clifton, CSG Systems International, ArcelorMittal, Denny's, Yamana Gold, and Egalet New Research Emphasizes Economic Growth GlobeNewswire
Mar-23-18 12:03PM  Egalet CEO: 'We are moving the company closer and closer to profitability' American City Business Journals -6.72%
Mar-22-18 03:50PM  Auditor raises questions about Egalet's future American City Business Journals -12.60%
02:26PM  [$$] Drug Maker Egalet Raises 'Going Concern' warning The Wall Street Journal
Mar-21-18 06:02AM  Egalet to Present at Upcoming Conferences PR Newswire
Mar-13-18 02:55AM  Edited Transcript of EGLT earnings conference call or presentation 12-Mar-18 12:30pm GMT Thomson Reuters StreetEvents
Mar-12-18 07:00AM  Egalet Corporation to Host Earnings Call ACCESSWIRE +17.33%
06:29AM  Egalet posts 4Q profit Associated Press
06:02AM  Egalet Reports Fourth Quarter and Full Year 2017 Financial Results PR Newswire
Feb-28-18 06:02AM  Egalet Announces a Large Regional Health Plan Placed ARYMO® ER and SPRIX® Nasal Spray in Preferred Formulary Positions PR Newswire
Feb-26-18 04:02PM  Egalet to Host Conference Call and Webcast to Discuss Fourth Quarter and Year-End 2017 Financial Results on March 12, 2018 PR Newswire +8.10%
Feb-20-18 06:02AM  Egalet Announces Issuance of New U.S. Patent for Guardian Technology PR Newswire
Feb-01-18 06:44AM  Egalet to Participate in Panel at BIO CEO & Investor Conference PR Newswire
Jan-29-18 06:02AM  Egalet Announces ARYMO® ER Data Published in Current Medical Research and Opinion Journal PR Newswire
Jan-25-18 08:25AM  Research Report Identifies Fate Therapeutics, A. Schulman, Celadon Group, Egalet, Meredith, and HCP with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire -6.02%
Jan-24-18 06:02AM  Egalet to Co-Host Category 1 Focus Group PR Newswire
Jan-23-18 06:02AM  Egalet's Partner OraPharma Begins Promotion of SPRIX® Nasal Spray PR Newswire
Jan-03-18 01:15PM  Egalet targeting dentists in co-promotion deal with Montco firm American City Business Journals
06:02AM  Egalet Partners with OraPharma to Co-Promote SPRIX® Nasal Spray PR Newswire
Dec-26-17 11:27AM  ETFs with exposure to Egalet Corp. : December 26, 2017 Capital Cube
Dec-22-17 10:00AM  EGLT: Debt Refinancing With Benefits Zacks Small Cap Research
Dec-20-17 08:16AM  Egalet Reduces Debt Obligation, Extends Maturity and Lowers Annual Interest Payments through Refinancing of Existing Convertible Notes PR Newswire -12.07%
Dec-18-17 07:40AM  Blog Exposure - FDA Granted Tentative Approval for Expanded Label for Egalets ARYMO ER Extended-Release Tablets C-II ACCESSWIRE
Dec-15-17 02:06PM  Egalet Corp (EGLT) Sparks Optimism Among Investors; Heres Why SmarterAnalyst +20.79%
06:02AM  Egalet Receives FDA Tentative Approval for Expanded Label for ARYMO® ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic Pain PR Newswire
Dec-05-17 12:43PM  ETFs with exposure to Egalet Corp. : December 5, 2017 Capital Cube
Nov-30-17 07:00AM  Wired News Egalet Shares Positive Top-Line Results from Phase-3 Study of Egalet-002 in Patients with Chronic Low Back Pain ACCESSWIRE +5.18%
Nov-28-17 06:02AM  Egalet Announces Positive Top-Line Results from Phase 3 Study Evaluating Efficacy and Safety of Egalet-002 in Patients with Moderate-to-Severe Chronic Low Back Pain PR Newswire +9.17%
Nov-22-17 03:00PM  EGLT: Impressive Prescription Growth; Revenues Should Follow Zacks Small Cap Research
Nov-20-17 12:19PM  ETFs with exposure to Egalet Corp. : November 20, 2017 Capital Cube
06:02AM  Egalet Received a Grant from InnoBooster to Develop a Novel Application of Guardian Technology PR Newswire
Nov-17-17 08:00AM  Todays Research Reports on Trending Tickers: Egalet Corporation and Intrexon Corporation ACCESSWIRE -12.61%
Nov-16-17 02:50PM  Egalet Announces Positive Top-Line Results from Phase 3 Safety Study Evaluating Safety of Egalet-002 PR Newswire +38.55%
Nov-15-17 12:17AM  Edited Transcript of EGLT earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-09-17 12:38PM  ETFs with exposure to Egalet Corp. : November 9, 2017 Capital Cube
08:53AM  Egalet Corp. :EGLT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 Capital Cube
Nov-08-17 06:40AM  Egalet Corporation to Host Earnings Call ACCESSWIRE
06:09AM  Egalet reports 3Q loss Associated Press
06:02AM  Egalet Announces Third Quarter 2017 Financial Results PR Newswire
Nov-06-17 06:02AM  Egalet Announces ARYMO ER Added to Large Payer Medicare Part D Formulary PR Newswire +7.81%
Oct-30-17 11:43AM  ETFs with exposure to Egalet Corp. : October 30, 2017 Capital Cube
06:02AM  Egalet to Present at Upcoming Scientific and Investor Conferences PR Newswire
Oct-25-17 06:02AM  Egalet to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results on November 8, 2017 PR Newswire
Oct-24-17 09:00AM  Egalet (EGLT): The Guardian of Misuse and Abuse Zacks Small Cap Research
Oct-20-17 10:11AM  ETFs with exposure to Egalet Corp. : October 20, 2017 Capital Cube
Oct-09-17 11:28AM  ETFs with exposure to Egalet Corp. : October 9, 2017 Capital Cube
Oct-06-17 09:13AM  Egalet Corp. :EGLT-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
Sep-18-17 06:02AM  National Lacrosse League and Egalet Corporation Announce Educational Partnership Around A Non-Narcotic Pain Option and Responsible Pain Management PR Newswire
Sep-08-17 06:02AM  Egalet Presented New Data at PAINWEEK Demonstrating Potential of ARYMO ER to Deter Opioid Abuse PR Newswire +6.87%
Sep-06-17 06:02AM  Egalet to Present at Investor Conferences this Fall PR Newswire
Sep-05-17 06:02AM  Egalet's Partner Ascend Therapeutics® U.S., LLC Begins Promotion of SPRIX® Nasal Spray PR Newswire
Aug-29-17 04:02PM  Egalet Announces Scientific Presentations at PAINWeek 2017 Meeting PR Newswire
Aug-16-17 10:10AM  Edited Transcript of EGLT earnings conference call or presentation 9-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-09-17 10:03PM  Egalet reports 2Q loss Associated Press
05:20PM  Egalet trims non-sales workforce by 40% American City Business Journals
04:02PM  Egalet Announces Second Quarter 2017 Financial Results and Expense Reduction Plan PR Newswire
10:30AM  Investor Network: Egalet Corporation to Host Earnings Call ACCESSWIRE
Jul-26-17 06:02AM  Egalet to Host Conference Call and Webcast on August 9, 2017 to Discuss Second Quarter 2017 Financial Results PR Newswire
Jul-11-17 04:02PM  Egalet Announces Closing of $30 Million Public Equity Offering PR Newswire +5.67%
Jul-06-17 09:24AM  Egalet Announces Pricing of Public Offering of Common Stock and Warrants PR Newswire -35.83%
08:50AM  3 Stocks to Watch on Thursday: Egalet Corp (EGLT), Herman Miller, Inc. (MLHR) and PriceSmart, Inc. (PSMT) InvestorPlace
07:45AM  Egalet's stock plunges toward record low after stock offering plan MarketWatch
Jul-05-17 04:01PM  Egalet Announces Proposed Public Offering of Common Stock and Warrants PR Newswire +6.28%
Jun-20-17 10:15AM  Egalet Stumbles Over FDA Complete Response Letter 24/7 Wall St. -17.77%
09:06AM  Egalet Receives Complete Response Letter from U.S. Food and Drug Administration for Prior Approval Supplement for 10 mg and 15 mg Dosage Strengths of OXAYDO PR Newswire
Jun-08-17 01:33PM  ETFs with exposure to Egalet Corp. : June 8, 2017 Capital Cube -7.03%
Jun-07-17 08:00AM  Today's Research Reports on Stocks to Watch: Egalet Corporation and 22nd Century Group Accesswire -6.91%
06:02AM  Egalet Partners with Ascend Therapeutics® U.S., LLC to Co-Promote SPRIX® Nasal Spray PR Newswire
Jun-06-17 06:02AM  Egalet Announces ARYMO® ER Added to Large Payer Formulary PR Newswire +17.02%
Jun-05-17 02:40PM  Patents piling up for Wayne maker of abuse-deterrent medicines American City Business Journals -5.24%
06:02AM  Egalet Announces Issuance of New U.S. Patent for Guardian Technology PR Newswire
May-26-17 01:06PM  ETFs with exposure to Egalet Corp. : May 26, 2017 Capital Cube
May-18-17 04:02PM  Egalet Announces Results of ARYMO® ER Harm Reduction Modeling Analysis PR Newswire
May-17-17 06:02AM  Egalet Announces ARYMO ER Data Published in Journal of Opioid Management and American Journal of Drug and Alcohol Abuse PR Newswire
May-15-17 03:38PM  ETFs with exposure to Egalet Corp. : May 15, 2017 Capital Cube
06:02AM  Egalet Announces Scientific Presentations at American Pain Society Meeting PR Newswire
May-12-17 11:24AM  Egalet Corp. :EGLT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube +10.18%
May-11-17 07:20AM  Panel of Leading Pain Management Specialists Highlight Potential Role of Abuse-Deterrent Formulations of Opioids and Non-Narcotics to Help Curb Misuse and Abuse at Egalet Investor Day PR Newswire -8.33%
May-10-17 06:22AM  Egalet reports 1Q loss Associated Press
06:02AM  Egalet Reports First Quarter 2017 Financial Results PR Newswire
Apr-26-17 06:02AM  Egalet to Report First Quarter 2017 Financial Results During Investor Day on May 10, 2017 in New York PR Newswire
Apr-18-17 06:23AM  Egalet Announces U.S. Food and Drug Administration Acceptance of File for Prior Approval Supplement for OXAYDO® (oxycodone HCl, USP) tablets C-II 10 mg and 15 mg Dosage Strengths PR Newswire
Apr-10-17 04:02PM  Egalet Corporation Announces Changes to Board of Directors PR Newswire
Apr-03-17 06:02AM  Egalet to Participate in Spring Investor Conferences PR Newswire
Mar-30-17 06:02AM  Egalet Deploys Salesforce to Begin Educating Healthcare Providers about ARYMO ER PR Newswire
Mar-29-17 02:35PM  The FDA News That Put The Wind Beneath Egalet Stock's Wings Benzinga +5.37%
11:25AM  Egalet Can Tout Abuse-Deterrent Opioid Painkiller Investopedia
Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shea Patrick MChief Commercial OfficerJan 02Sale1.0091091037,020Jan 03 04:58 PM
Shea Patrick MChief Commercial OfficerOct 02Sale1.309101,18337,930Oct 03 05:02 PM
Strobeck MarkChief Operating OfficerOct 02Sale1.298,70011,22312,080Oct 03 05:03 PM
Musial StanChief Financial OfficerJul 03Sale2.363,4808,21342,407Jul 06 04:49 PM
Shea Patrick MChief Commercial OfficerJul 03Sale2.359102,13938,840Jul 06 04:48 PM
VARKI PAULSVP, GC & Chief Compliance OffJul 03Sale2.358061,89429,514Jul 06 04:47 PM
Strobeck MarkChief Operating OfficerJun 30Sale2.398,70020,79320,780Jul 05 06:26 PM